Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.

PLoS genetics - 1 Sept 2018

Hamieh Lana, Choueiri Toni K, Ogórek Barbara, Khabibullin Damir, Rosebrock Daniel, Livitz Dimitri, Fay Andre, Pignon Jean-Christophe, McDermott David F, Agarwal Neeraj, Gao Wenhua, Signoretti Sabina, Kwiatkowski David J

Abstract excerpt

The mechanistic target of rapamycin (mTOR) is an established therapeutic target in renal cell carcinoma (RCC). Mechanisms of secondary resistance to rapalog therapy in RCC have not been studied previously. We identified six patients with metastatic RCC who initially responded to mTOR inhibitor therapy and then progressed, and had pre-treatment and post-treatment tumor samples available for analysis. We performed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to Epigenesis, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Everolimus

Share to Exome Sequencing

Share to Genetic Heterogeneity

Share to Kidney Neoplasms

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 30256787
DOI: 10.1371/journal.pgen.1007679
PMCID: PMC6181431

Genes

PBRM1
MTOR
PTEN
TSC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.PMID 30256787Read ↗

Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma.Semantic proximity Read ↗

PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinomaSemantic proximity Read ↗

Unconventional mechanism of action and resistance to rapalogs in renal cancer.Semantic proximity Read ↗

Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor TherapySemantic proximity Read ↗

Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.Semantic proximity Read ↗

Molecular Mechanisms of Drug Resistance in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.Semantic proximity Read ↗

Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.Semantic proximity Read ↗

Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.